NCT03487198View on ClinicalTrials.gov

The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder

PHASE3TerminatedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

May 30, 2019

Study Completion Date

May 30, 2019

Conditions
Major Depressive Disorder
Interventions
DRUG

Brexpiprazole

Brexpiprazole 2-3mg/day

DRUG

Placebo

Placebo 2-3 mg/day

Trial Locations (1)

100088

Beijing Anding Hospital of Capital Medical University, Beijing

Sponsors
All Listed Sponsors
lead

Otsuka Beijing Research Institute

INDUSTRY